Enríquez AB, Baumal CR, Crane AM, et al. - In this retrospective case series, researchers sought to analyze early outcomes associated with brolucizumab injection for neovascular age-related macular degeneration (nAMD). This investigation was carried out at 15 private or academic ophthalmological centers in the United States. Between October 17, 2019, and April 1, 2020, all consecutive patients with eyes treated with brolucizumab by 6 retina specialists were included. In total, 172 eyes from 152 patients (87 women [57.2%]; mean [SD] age, 80.0 [8.0] years) were involved. VA remained stable with a decrease in central subfield thickness in this study of brolucizumab IVI for nAMD. In one eye, intraocular inflammation ranged from mild to severe occlusive retinal vasculitis, which resolved spontaneously.